News & Updates
Filter by Specialty:
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.
Olanzapine vs fosaprepitant: Which is better for CINV prevention?
09 May 2024
Is topical better than standard steroid after cataract surgery?
Soft topical steroid application and standard steroid treatment demonstrate similar efficacy and safety in patients who underwent cataract surgery, reports a study.
Is topical better than standard steroid after cataract surgery?
07 May 2024
NCHT improves PFS in locally advanced prostate cancer
Neoadjuvant chemohormonal therapy (NCHT) plus radical prostatectomy (RP) confers significant biochemical progression-free survival (bPFS) benefits relative to neoadjuvant hormonal therapy (NHT) plus RP on patients with high-risk, locally advanced prostate cancer, reports a study.
NCHT improves PFS in locally advanced prostate cancer
06 May 2024
MIRASOL PRO data boost mirvetuximab soravtansine potential in FRα-positive ovarian cancer
Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.
